Bio-ACT
Research type
Research Study
Full title
Development of a Biomarker Directed Strategy to Amelioriate Common Toxicites From Conventional Chemotherapy (Bio-ACT)
IRAS ID
119526
Contact name
Malcolm Ranson
Contact email
Research summary
Side-effects from chemotherapy can be severe in some patients leading to admission to hospital, a worse quality of life and delays in subsequent doses of chemotherapy. A blood test that could predict patients who will go on to develop severe side-effects could be useful and might allow early intervention with medicines to reduce the severity of the symptoms and prevent admission to hospital.
This study will collect blood samples from patients with lymphoma or sarcoma who are receiving chemotherapy (with an expected admission rate for neutropenic sepsis, one of the side-effects that most commonly results in hospital admission, of less than 20%). It will assess whether changes in blood proteins (“biomarkers”) taken 2 days after the 1st chemotherapy can predicts subsequent severe side-effects throughout the 4 months of chemotherapy. In addition we will collect data on quality of life and contact with medical professionals to assess the costs of chemotherapy toxicity to both the patient and health service. This will allow us in the future to model the cost-effectiveness of using biomarkers in this manner to try and reduce chemotherapy toxicity.
REC name
North West - Greater Manchester East Research Ethics Committee
REC reference
13/NW/0493
Date of REC Opinion
22 Jul 2013
REC opinion
Favourable Opinion